Anti-doping agency to ban all gene editing in sport from 2018
By Michael Le Page,
New Scientist
| 10. 09. 2017
The battle between sports cheats and testers is poised to enter a whole new arena. The World Anti-Doping Agency has extended its 2003 ban on “gene doping” to include all forms of gene editing – but it is not clear the agency has the means to enforce this ban.
WADA already bans the use of genetically modified cells and gene therapy if they have “the potential to enhance sport performance”. From 2018, the list will also include “gene editing agents designed to alter genome sequences and/or the transcriptional or epigenetic regulation of gene expression”.
Gene editing involves tweaking existing genes, rather than adding whole new ones to a person’s body. The field is advancing incredibly fast thanks to the development in 2012 of an easy editing method called CRISPR. The first human trials of the method are already underway.
Whether people who have medical treatment involving such methods will be able to later compete in sports depends on the nature of the treatment, says WADA spokesperson Maggie Durand.
“Generally, performance enhancement implies enhancement beyond a return to normal...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...
By Staff, The Medicine Maker | 03.21.2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later...